At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 13 enrolled
Drug / intervention
Clavulanic Acid +1 moredrug
Likely dose
Clavulanic Acid 250mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1B Double Blind, Placebo (PBO) Controlled, Pharmaco- Magnetic Resonance Spectroscopy (MRS) Inpatient Study of Clavulanic Acid (CLAV) 500, 750, 1000 mg Daily Repeated Administration in Early Remitted Cocaine Use Disorder Subjects
In Brief
A Phase 1 clinical trial evaluating Clavulanic Acid and Placebo for Cocaine Dependence. Completed, enrolled 13 participants across 1 site.
Detailed Summary
A dose-escalation study to determine the optimum dose of Clavulanic Acid (CLAV) for effects on craving and efficacy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCocaine Dependence
CountriesUnited States
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartSep 2020
Primary CompletionNov 2021
Study CompletionMar 2022
TodayJul 2026
First PostedJun 2, 2020
Enrollment StartSep 1, 2020
Primary CompletionNov 23, 2021
Study CompletionMar 31, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 6.1 years ago
Interventions
Clavulanic Aciddrug
Drug will be given in 250mg capsules.
Placeboother
Placebo